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Abstract: Successful treatment of inhalation anthrax, pneumonic plague and tularemia can be achieved with fluoroqui-
nolone antibiotics, such as ciprofloxacin and levofloxacin, and initiation of treatment is most effective when administered 
as soon as possible following exposure. Bacillus anthracis Ames, Yersinia pestis CO92, and Francisella tularensis SCHU 
S4 have equivalent susceptibility in vitro to ciprofloxacin and levofloxacin (minimal inhibitory concentration is 0.03 
μg/ml); however, limited information is available regarding in vivo susceptibility of these infectious agents to the fluoro-
quinolone antibiotics in small animal models. Mice, guinea pig, and rabbit models have been developed to evaluate the 
protective efficacy of antibiotic therapy against these life-threatening infections. Our results indicated that doses of cipro-
floxacin and levofloxacin required to protect mice against inhalation anthrax were approximately 18-fold higher than the 
doses of levofloxacin required to protect against pneumonic plague and tularemia. Further, the critical period following 
aerosol exposure of mice to either B. anthracis spores or Y. pestis was 24 h, while mice challenged with F. tularensis 
could be effectively protected when treatment was delayed for as long as 72 h postchallenge. In addition, it was apparent 
that prolonged antibiotic treatment was important in the effective treatment of inhalation anthrax in mice, but short-term 
treatment of mice with pneumonic plague or tularemia infections were usually successful. These results provide effective 
antibiotic dosages in mice, guinea pigs, and rabbits and lay the foundation for the development and evaluation of combi-
national treatment modalities.  
Keywords: Anthrax, plague, tularemia, ciprofloxacin, levofloxacin, animal models. 
INTRODUCTION 
  Antibiotics are still considered to be the most effective 
therapeutic regimen in the treatment of patients with inhala-
tion anthrax, pneumonic plague, and tularemia, although new 
treatment modalities, for example, with human monoclonal 
antibodies against protective antigen (PA) of Bacillus an-
thracis [1-5] and antitoxic drugs [6-8] are being developed, 
along with new second generation prophylactic vaccines [9-
11]. It is likely that new therapeutics against these infections 
would be used in combination with effective antibiotics, and 
knowing dose and blood concentrations in different labora-
tory animal species would be essential for combinational   
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studies in small animal models. Currently, two antibiotics 
have been approved by the U.S. Food and Drug Administra-
tion for the treatment of inhalation anthrax, ciprofloxacin 
and levofloxacin. Anthrax also can be effectively treated 
with other antibiotics including penicillin, tetracycline and 
streptomycin. Likewise, streptomycin, tetracycline, and gen-
tamicin are antibiotics of choice against plague and tularemia 
[12-15]. Although currently, there is no available vaccine 
against plague, a recombinant vaccine containing capsular 
antigen (F1) and low calcium response antigen V (LcrV) has 
shown promising results in mouse and non-human primate 
models [16, 17]. Likewise, a live attenuated vaccine strain 
(LVS) of F. tularensis is approved for vaccination of mili-
tary personnel and those investigators working with this 
pathogen [18]. 
  The fluoroquinolones exhibit extensive tissue penetra-
tion, concentration-dependent killing and a prolonged post-
antibiotic effect against susceptible bacteria [19]. Pharma-Protection Against Anthrax, Plague, and Tularemia  The Open Microbiology Journal, 2010, Volume 4    35 
codynamic data from in vitro, large animal, and human stud-
ies suggest that fluoroquinolone efficacy is associated with 
achieving a maximum serum concentration (Cmax) to mini-
mum inhibitory concentration (MIC) ratio (Cmax/MIC) of 
>10 and area under the 24-hour serum concentration-time 
curve to MIC ratio (AUC/MIC) of >125 for most gram-
negative bacteria [19-21]. For most gram-positive organisms, 
a lower 24-hour AUC/MIC ratio of >25 is required for opti-
mal bacterial eradication [22]. Published pharmacodynamic 
data involving fluoroquinolones against B. anthracis [23-25] 
Y. pestis [26-28], or F. tularensis [29-31] are mostly limited 
to murine models; however, fluoroquinolone data against 
anthrax derived from in vitro modeling studies [32, 33] and 
nonhuman primate models [34-36] have been reported.  
  From a recent study conducted by Ambrose and col-
leagues [23] evaluating gatifloxacin in a murine model of B. 
anthracis inhalation infection, it was shown that the 
AUC24/MIC ratio is the pharmacodynamic parameter that 
best predicts outcome with 90% and 99% effective doses 
corresponding to AUC24/MIC ratios of 15.8 and 30, respec-
tively. These degrees of fluoroquinolone exposure that pre-
dict a desirable outcome in mice correspond to a AUC24/MIC 
ratio of about 200-300 in humans [37]. Among the few stud-
ies of fluoroquinolone administration in the guinea pig and 
rabbit models of inhalation anthrax are reports by Altboum 
et al. [38], Shoop et al. [39], and Peterson et al. [4]. Since 
these are important small animal models for development of 
new treatment modalities against anthrax, plague, and tula-
remia, the current findings provide important information on 
dosing and blood levels of the fluoroquinolones useful in the 
development of adjunctive therapies [37, 40, 41]. 
  In addition to their direct antimicrobial effects, it is well 
recognized that fluoroquinolones possess potent concentra-
tion-dependent immunomodulatory properties [42]. In par-
ticular, they have been shown to protect mice from lipopoly-
saccharide (LPS)-induced death, presumably by decreasing 
the production/secretion of proinflammatory mediators such 
as tumor necrosis factor-alpha (TNF-), interleukins (IL)-1 
/, -6, -8 and -12 [43, 44]. Further, enhancement of hema-
topoietic stimulating factors such as IL-2, IL-33 and pulmo-
nary production of granulocyte-macrophage colony stimulat-
ing factor (GM-CSF) has been associated with fluoroqui-
nolone treatment in various animal models [45, 46]. The 
underlying mechanisms of these immunomodulatory proper-
ties are not well defined, but may involve their effects on 
signal transduction, intracellular transcription factors, and/or 
interactions with the type II topoisomerase complex [42]. 
  In this report, we chose the nasal instillation models of 
inhalation anthrax with Swiss-Webster mice, Hartley guinea 
pigs, and Dutch-belted rabbits to evaluate the protection af-
forded by ciprofloxacin and levofloxacin. Similarly, we 
evaluated the effectiveness of levofloxacin against pneu-
monic plague and tularemia using murine models. For the 
latter two diseases, we preferred to use only levofloxacin as 
our studies with anthrax indicated that it was as efficacious 
or better than ciprofloxacin and could be given to animals 
only once per day compared to ciprofloxacin that needed to 
be given to animals twice because of its shorter half life. 
Pharmacokinetic studies in all three animal models were 
designed to provide information about the blood levels of 
both antibiotics in the animals challenged with these patho-
gens. The results may be beneficial as a guide to health 
authorities in selecting antibiotic dose levels for patients in 
the event of future acts of bioterrorism involving these select 
agents. 
MATERIALS AND METHODOLOGY 
Antibiotics 
  Sterile, injectable formulations of ciprofloxacin (Bayer 
Pharmaceuticals Corp., West Haven, CT) and levofloxacin 
(Janssen Pharmaceutica, N.V., Beerse, Belgium) were pur-
chased from the UTMB Pharmacy. Although normally in-
fused intravenously into patients as 5% levofloxacin and 
0.2% ciprofloxacin in 5% dextrose solution, respectively, 
animals in this study were injected with the antibiotics by the 
subcutaneous or intraperitoneal routes in the amounts indi-
cated in the Results section. 
MIC of Ciprofloxacin and Levofloxacin Against B.  
anthracis, Y. pestis, and F. tularenesis 
  The MIC of ciprofloxacin and levofloxacin against vari-
ous pathogens was determined by using the E-Test (AB Bio-
disk North America Inc, Culver City, CA) [47]. Briefly, the 
overnight-grown bacterial cultures were diluted (1:4) with 
fresh Luria-Bertani (LB) medium and continued to grow at 
28°C for Y. pestis CO92 and 37
oC for B. anthracies Ames 
and F. tularenesis SCHU S4 for 2 h (OD600nm of 0.6). The 
bacterial cultures were then spread evenly onto the Mueller–
Hinton agar plates (Becton Dickinson, Cockeysville, MD) or 
on 5% sheep blood agar (SBA) plates (Teknova, Hollister, 
CA), and the predefined levofloxacin (range of 0.002 to 32 
g/ml) E-strips were placed onto the plates. Plates were in-
cubated for 48 h at either 28°C or 37
oC, and the MIC values 
were recorded. 
Preparation of B. anthracis spores 
  Spores were prepared by inoculating B. anthracis Ames 
strain in Schaeffer's sporulation medium [48] as we previ-
ously described [7]. We confirmed sporulation to be at >99% 
via phase contrast microscopy and the Wirtz spore stain [49]. 
Aliquots of the stock spore suspension (1 x 10
9 to 1 x 10
10 
cfu/ml) were stored at –70
oC, and freshly diluted in phos-
phate-buffered saline (PBS) to the desired colony forming 
units (cfu) immediately before each animal challenge ex-
periment.  
Preparation of Y. pestis CO92 culture 
 Virulent  Y. pestis strain CO92 was obtained from the 
Centers for Disease Control and Prevention (CDC), Atlanta, 
GA. To prepare Y. pestis cultures, we followed our recently 
described protocol [50, 51].  
 B.  anthracis cultures and spores as well as Y. pestis cul-
tures were prepared and stored in a restricted access BSL-2 
laboratory registered with the CDC and inspected by the 
Department of Defense and the United States Department of 
Agriculture. 
Preparation of F. tularenesis SCHU S4 culture 
  An aliquot of stock was plated on cysteine heart infusion 
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37°C with 5% CO2. Bacterial colonies were expanded in 
modified Mueller-Hinton II broth supplemented with IsoVi-
taleX (Becton Dickinson, Cockeysville, MD) for 10 h with 
shaking at 37°C. After centrifugation, bacterial pellets were 
resuspended in PBS, the cell number determined with a Pet-
roff-Hausser cell counting chamber (Hausser Scientific, Hor-
sham, PA), and adjusted to the desired concentrations by 
diluting in PBS [52]. F. tularenesis culture was stored and 
cultivated in the CDC approved BSL-3 laboratory. 
Challenge of Mice, Guinea Pigs, and Rabbits Via  the  
Intranasal Route  
  To evaluate the protective efficacy of ciprofloxacin and 
levofloxacin in vivo, we challenged 8-week-old (25 to 30-g) 
female Swiss-Webster mice (Taconic, Germantown, NY) 
and 250 to 300-g Hartley guinea pigs (Charles River Labora-
tories, Wilmington, MA) with 5 x 10
4 cfu and 6 x 10
5 cfu of 
B. anthracis Ames spores, respectively. Swiss-Webster mice 
were also challenged with 5 LD50 (1.7 x 10
3) of Y. pestis 
CO92. BALB/c mice were challenged with 3 LD50 (1.7 x 10
2 
cfu) doses of F. tularensis SCHU S4. Dutch-belted rabbits 
(0.7-1.1 kg; Myrtle’s Rabbitry, Inc., Thompson Station, TN) 
were challenged with 100 LD50’s (1 x 10
7 cfu) of B. an-
thracis Ames spores. 
  Mice and guinea pigs were anesthetized by intraperito-
neal (i.p.) and subcutaneous (s.c.) routes, respectively, with a 
mixture of ketamine-HCl (48 mg/kg for mice and 30 mg/kg 
for guinea pigs) and xylazine-HCl (9.6 mg/kg for mice and 7 
mg/kg for guinea pigs). Rabbits were anesthetized with 
ketamine (35 mg/kg) and xylazine (5 mg/kg) by intramuscu-
lar (i.m.) injection. For spore/bacteria instillation in animals, 
we used the method of Comer et al. [7]. The challenge vol-
ume was 20 μl/naris for mice, 25 μl/naris for guinea pigs, 
and 50 μl/naris for rabbits. PBS (20, 25, and 50 μl/naris) was 
then used to wash any non-adherent spores from the nasal 
cavity into the lungs for each animal species, respectively. 
All animal challenges were performed in a select agent-
approved, restricted-access Animal Biosafety Level 3 Labo-
ratory under approved protocols in accordance with guide-
lines recommended by the National Institutes of Health, 
Centers for Disease Control, and United States Department 
of Agriculture. In the animal studies, antibiotics were given 
24 h post infection or at various delayed time points as indi-
cated for a period of 6-13 days. In mice, the antibiotics were 
given by the i.p. route, in guinea pigs by the s.c. route, while 
in rabbits, antibiotics were injected via the i.m. route. 
Fluoroquinolone Assay 
  All serum specimens were assayed by the reversed-phase 
high-performance liquid chromatographic (HPLC) method 
with fluorescence detection as previously described [53-54].  
Pharmacokinetic Studies and Analysis 
  Studies in mice were performed using a sample size of 
n=4 at each time point (e.g., 0, 0.25, 1, 1.5, 2, 4, 6, 12, 24, 36 
and 48 h) following dose administration of ciprofloxacin (90 
mg/kg [i.p.]) and levofloxacin (5 and 90 mg/kg [i.p.]). Stud-
ies in guinea pigs (n=8 per regimen: ciprofloxacin 15 mg/kg 
[s.c.] and levofloxacin 8.5 mg/kg [s.c.]) and rabbits (n=10 
per regimen: ciprofloxacin 10 mg/kg [i.m.]; levofloxacin 7.1 
mg/kg [i.m.]) were conducted, which provided n=6 serum 
concentrations over the 48 h time period. The dose of each 
fluoroquinolone was based on the effective dose for 100% of 
the animals (ED100) as determined from the survival studies. 
  The serum concentration-time data were analyzed by 
standard noncompartmental methods [55]. The maximum 
concentration (Cmax) in serum and the time to reach Cmax 
(Tmax) were determined directly from the individual concen-
tration data. The terminal elimination rate constant (z) was 
obtained by least-squares regression of the log serum drug 
concentrations in the log-linear phase. A minimum of three 
concentration-time points were used to represent the log-
linear phase for rabbits and guinea pigs in which each animal 
provided multiple serum specimens for concentration deter-
mination. Composite data were used to assess this parameter 
in mice. The elimination half-life (t) was calculated by di-
viding 0.693 by z. The area under the concentration-time 
curve for ciprofloxacin and levofloxacin from time zero 
(predose) to infinity (AUC0-) was calculated by the linear 
trapezoidal rule with extrapolation to infinity, using Ct/z, 
where Ct is the last measurable concentration. The apparent 
total body clearance (TBC) was calculated by the adminis-
tered dose divided by AUC0-. 
Statistics 
  All of the animal survival data were analyzed with the 
Fisher’s exact test using the SigmaStat Statistical package 
(SYSTAT, Richmond, CA). Pharmacokinetic parameters for 
ciprofloxacin and levofloxacin within species were com-
pared using the Student’s t-test unless normality failed in 
which case the nonparametric Mann-Whitney rank sum test 
was employed. All statistical tests were performed at the 5% 
level of significance. Results were expressed as means ± 
standard deviations, with the exception of Tmax values, which 
were given as the median (range).  
RESULTS  
LD50 doses for B. anthracis, Y. pestis, and F. tularensis 
 Table  1 lists the LD50 doses of the above-mentioned 
agents in Swiss-Webster and BALB/c mice. These three   
bacterial pathogens could be ranked in order of decreasing 
infectivity based on LD50 dose in a murine model; F. tu-
larensis > Y. pestis > B. anthracis. Based on these data,   
we elected to use Swiss-Webster mice for the study of   
B. anthracis and Y. pestis, while the increased sensitivity   
of BALB/c mice influenced our selection of this species   
for the study of F. tularensis. Also shown are the LD50  
values of B. anthracis Ames spores for Hartley guinea pigs 
and Dutch-belted rabbits. 
Ciprofloxacin and Levofloxacin Protect Mice Against 
Inhalation Exposure to B. anthracis Ames spores 
 Fig.  (1A) illustrates that administration of ciprofloxacin 
in doses of 90-120 mg/kg/day (b.i.d.) was required to 
achieve complete protection during treatment of Swiss-
Webster mice against challenge with 5 LD50 of B. anthracis 
spores, but sustained treatment was essential. The highest 
dose of 180 mg/kg/day appeared to reach a toxic level, since 
survival decreased compared to that of 90-120 mg/kg/day 
doses. Ciprofloxacin doses of 60 mg/kg/day or below were 
not protective. Interestingly, even relatively high doses of Protection Against Anthrax, Plague, and Tularemia  The Open Microbiology Journal, 2010, Volume 4    37 
Table 1.  Fifty Percent Lethal Dose (LD50) of B. anthracis, Y. pestis, and F. tularensis in Laboratory Animals Using Nasal Instillation 
Animal Model  B. anthracis Ames Spores (cfu)  Y. pestis CO92 Cells (cfu)  F. tularensis SCHU S4 Cells (cfu) 
Swiss-Webster Mice  1.1 x 10
4  3.4 x 10
2  2.2 x 10
2 
BALB/c Mice  1.7 x 10
4  1.0 x 10
2  3.3 x 10
1 
Hartley Guinea Pigs  1.2 x 10
5 N.D. N.D. 
Dutch-belted Rabbits  1.0 x 10
5 N.D. N.D. 
N.D. = Not done. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). A. Protection afforded to Swiss-Webster mice by various doses of ciprofloxacin initiated 24 h after intranasal challenge with 5 LD50 
of B. anthracis Ames spores. One-half the daily dose was administered every 12 h. The LD50 dose was previously determined in the nasal 
instillation model [4]. The horizontal bar indicates the period of ciprofloxacin treatment (6 days). The two highest doses were significant from 
days 2 through 11.5, while 90 mg/kg/day was significant from days 2 through 16.5. Significance for the 60 mg/kg/day group was delayed 
until day 3.5 and only remained so until day 4.5. Significance at 30 mg/kg/day was only at days 2 and 2.5, while the lowest dose showed no 
significance. B. Protection afforded to Swiss-Webster mice by various doses of levofloxacin. The daily dose was administered once every 24 
h. The horizontal bar indicates the period of levofloxacin treatment (13 days). All groups, except the lowest dose, was significant beginning at 
day 2 and continued through the end of the study. Significance from the control was determined by the Fisher Exact Test (p<0.05).   38    The Open Microbiology Journal, 2010, Volume 4  Peterson et al. 
 
ciprofloxacin that were completely protective during short-
term therapy failed to provide long-term survival once treat-
ment ceased. Within the period of treatment, a dose of ap-
proximately 70 mg/kg/day was the ED50 for ciprofloxacin in 
these mice; however, mouse deaths occurred after antibiotic 
administration ceased. 
  During treatment, doses of 90-120 mg/kg/day of 
levofloxacin were completely protective for Swiss-Webster 
mice challenged with 5 LD50 of B. anthracis Ames spores 
(Fig. 1B). Like for ciprofloxacin, some toxicity of the antibi-
otic was noted at the highest dose of 180 mg/kg/day. 
Levofloxacin in doses of 30-60 mg/kg/day provided ap-
proximately 70% protection, while the lowest dose of 15 
mg/kg/day of levofloxacin was ineffective. Further, as noted 
with ciprofloxacin, once treatment with higher doses ceased, 
mice began to die of anthrax. In this study, we opted to treat 
animals for 13 days with levofloxacin, although in our sub-
sequent experiments, we reduced the treatment time to 6 
days with similar results. 
Protection of Hartley Guinea Pigs Against Inhalation 
Anthrax with Ciprofloxacin and Levofloxacin 
  All guinea pigs challenged with 5 LD50 of B. anthracis 
Ames spores were completely protected while being injected 
with doses of ciprofloxacin equal to or greater than 15 
mg/kg/day; however, deaths began to occur 6 days after the 
antibiotic treatment ceased (Fig. 2). Identical protection re-
sults were observed in other guinea pigs challenged with 25 
LD50 of B. anthracis spores (data not shown). By titrating the 
antibiotic dose, we were able to establish a threshold, non-
protective dose (3.7 mg/kg/day), which we have used in syn-
ergy studies with other treatment modalities [4]. We were 
unable to establish an ED50 dose of ciprofloxacin in guinea 
pigs against inhalation anthrax, since regardless of antibiotic 
dose, all animals eventually succumbed to the infection after 
treatment ceased; however, during treatment the ED50 was 
estimated to be 8.8 mg/kg/day. 
  Levofloxacin provided 80% protection to guinea pigs, 
during sustained treatment with doses 8.5-17 mg/kg/day 
against inhalation anthrax; however, the lowest dose of 
levofloxacin (e.g., 4.2 mg/kg/day) was ineffective in protect-
ing the animals during treatment. Upon cessation of treat-
ment at 6 days, death of most of the animals ensued even at 
higher doses of 8.5 and 17 mg/kg/day (data not shown). 
Protection of Dutch-Belted Rabbits Against Inhalation 
Anthrax with Ciprofloxacin and Levofloxacin 
 Fig.  (3A) depicts the amount of protection afforded to 
rabbits against inhalation anthrax using 100 LD50 of B. an-
thracis spores when various doses of ciprofloxacin were ad-
ministered 24 h post-challenge for 6 days. A 10 mg/kg/day 
dose regimen of ciprofloxacin provided 80% protection. Un-
like the results obtained in similar experiments with mice 
and guinea pigs, cessation of short-term treatment with 
ciprofloxacin did not result in increased mortality. The ED50 
of ciprofloxacin against inhalation anthrax in the rabbit 
model was 7.5 mg/kg/day (Table 3); however, due to the 
short half-life of the drug, ciprofloxacin was given twice 
each day. 
  As shown in Fig. (3B), levofloxacin was equal to or 
slightly better than ciprofloxacin in protecting rabbits against 
inhalation anthrax, and the drug could be given once per day. 
A levofloxacin dose of >7 mg/kg/day was completely protec-
tive. The ED50 of levofloxacin against anthrax in rabbits was 
determined to be 4.0 mg/kg/day (Table 3) when given by the 
s.c. route. Like for ciprofloxacin, we did not observe further 
deaths after cessation of the levofloxacin treatment. Fig. (4) 
shows the effect of delaying treatment with levofloxacin in 
the rabbit model against inhalation anthrax. In this study, 
levofloxacin treatment was initiated at various times post 
challenge and continued for 13 days. Complete protection of 
the rabbits was achieved during the 13 days of treatment, 
when initiated 24 h post challenge, but dropped to 83% (1 
death) after treatment ceased. In comparison, when initiation 
 
 
 
 
 
 
 
 
 
Fig. (2). Survival of Hartley guinea pigs treated with varying doses of ciprofloxacin 24 h after intranasal challenge with 5 LD50 of B. an-
thracis Ames spores. The horizontal bar indicates the period of treatment (6 days). The three highest doses were significant from days 3.5 
through 11.5. The lower three doses were significant beginning at day 3.5, but ended at day 10 for the 15 mg/kg/day group, day 3.5 for the 
7.5 mg/kg/day group, and day 3 for the 4 mg/kg/day group. Significance from the control was determined by the Fisher Exact Test (p<0.05). Protection Against Anthrax, Plague, and Tularemia  The Open Microbiology Journal, 2010, Volume 4    39 
of treatment was delayed until 48 h postinfection, survival 
dropped to 40% during treatment and was maintained at this 
level until the end of the study. Further delay in initiating 
levofloxacin treatment as late as 57, 72, or 96 h was com-
pletely ineffective in protecting the rabbits. We preferred to 
treat the animals with levofloxacin for 13 days in this ex-
periment for its protective effects as the antibiotic treatment 
was delayed after challenge. 
Levofloxacin Protects Mice Against Inhalation Exposure 
to Y. pestis CO92 
  Swiss-Webster mice were challenged with 5 LD50 of Y. 
pestis, and 24 h postinfection were injected by the i.p. route 
with various doses (0.1-15 mg/kg/day) of levofloxacin for 6 
days. Complete protection of the mice against pneumonic 
plague was achieved with doses of levofloxacin equal to or 
greater than 5 mg/kg/day, and 1 mg/kg/day yielded 80% pro-
tection. No protection of animals was observed at lower 
doses of levofloxacin (0.5 and 0.1 mg/kg/day) with 5 LD50 of 
Y. pestis CO92 (Fig. 5A). The ED50 of levofloxacin for com-
pletely protecting mice against pneumonic plague was 0.7 
mg/kg/day (Table 3).  
  Even though initiation of the 6 day levofloxacin treat-
ment (5 and 10 mg/kg/day) was delayed as late as 24 h post-
challenge with Y. pestis (Fig. 5B), 100% of the mice sur-
vived; whereas, 90% survival was observed when treatment 
with levofloxacin was delayed as late as 36 h. In contrast, a 
delay in treatment with levofloxacin as late as 48 h resulted 
in only 10-20% survival. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). A. Survival of Dutch-belted rabbits treated with various doses of ciprofloxacin for six days beginning 24 h after nasal instillation 
challenge with 100 LD50 B. anthracis Ames spores. The horizontal bar indicates the period of treatment (6 days). The highest dose was sig-
nificant starting at day 3 and continuing through the end of the study. Significance for the 5 mg/kg/day group only lasted for days 2.5 and 3, 
while the two lowest doses were not significant. Significance from the control was determined by the Fisher Exact Test (p<0.05). B. Survival 
of Dutch-belted rabbits treated with various doses of levofloxacin. For all groups, significance (p<0.05) started on day 2.5, and while the two 
highest doses were significant through the end of the study, the 3.57 mg/kg group was only significant through day 4, and 1.78 mg/kg/day, 
only through day 3. 40    The Open Microbiology Journal, 2010, Volume 4  Peterson et al. 
Levofloxacin Protects Mice Against Inhalation Exposure 
to F. tularensis SCHU S4 
 Fig.  (6A) shows that 13 days of levofloxacin treatment, 
initiated 24 h post-challenge, in concentrations (0.5-10 
mg/kg/day) completely protected the mice against tularemia 
during treatment. After treatment with levofloxacin at 1 
mg/kg/day ceased, a death occurred. At the lowest dose of 
0.1 mg/kg/day, animals succumbed to infection during the 
antibiotic treatment, which progressively increased to 50% 
survival (Table 3) after cessation of antibiotic therapy. We 
preferred 13 days of antibiotic treatment as F. tularenesis is 
an intracellular pathogen, and we suspected that longer 
treatment might be required for observing protection. 
 Fig.  (6B) illustrates that initiation of levofloxacin treat-
ment (40 mg/kg/day) for 13 days in mice infected with F. 
tularensis could be delayed as long as 72 h postchallenge 
and still achieve 100% protection. Even when levofloxacin 
treatment was delayed as late as 96 h, 80% of the mice sur-
vived; however, delay until 120 h resulted in no protection. 
Pharmacokinetics and ED50/ED100 of Ciprofloxacin and 
Levofloxacin 
 Table  2 lists the pharmacokinetic parameters of cipro-
floxacin and levofloxacin for each of the three models based 
on ED100 dosing. Within each animal species, the Cmax, 
AUCs, elimination T, and TBC values were remarkably 
similar between the two fluoroquinolones, despite the 
slightly higher milligram per kilogram dose required for 
ciprofloxacin to achieve the same efficacy in the guinea pig 
and rabbit models. The only significantly different parame-
ters included higher peak serum concentrations of levoflox-
acin compared to ciprofloxacin (45.2 ± 10.3 μg/ml vs. 25.5 ± 
10.3 μg/ml, P < 0.001) in mice receiving the same 90 mg/kg 
dose and a longer T of levofloxacin versus ciprofloxacin in 
the rabbit model (2.8 ± 1.2 h vs 1.5 ± 0.7 h, P = 0.009). The 
mean elimination half lives of both agents ranged from 1.4 to 
2.8 hours in all three species. 
 Table  3 shows a summary of the antibiotic dose protec-
tion data providing ED50 and ED100 values against inhalation 
anthrax in the three different animal models. The ED50 val-
ues for ciprofloxacin and levofloxacin against inhalation 
anthrax in Swiss-Webster mice were 70 and 28 mg/kg/day, 
respectively. When ciprofloxacin and levofloxacin were 
tested against anthrax in the guinea pig model, the ED50 val-
ues were 8.8 and 5.0 mg/kg/day, respectively. Similarly, we 
determined that the ED50s of ciprofloxacin and levofloxacin 
against anthrax using rabbits were 7.5 and 4.0 mg/kg/day, 
respectively. The ED50 values for levofloxacin in mice in-
fected with Y. pestis and F. tularensis were 0.7 and 0.1, re-
spectively (Table 3). 
DISCUSSION 
  The infectivity profile (Table 1) of the three bacterial 
pathogens revealed that F. tularensis SCHU S4 and Y. pestis 
CO92 had lower LD50’s than B. anthracis Ames, when the 
agents were administered by nasal instillation. In related 
experiments (in mice), the virulence of all three select 
agents, when administered by subcutaneous injection, was 
essentially the same, that is, approximately 5-6 cells/spores 
per animal (data not shown). With a low LD50 nasal instilla-
tion dose of 33 cells in BALB/c mice, F. tularensis barely 
exceeded the infectivity of Y. pestis, which was 100 cells. In 
Swiss-Webster mice, the LD50s of these two pathogens were 
about two logs lower than that of B. anthracis Ames spores. 
The LD50’s for B. anthracis Ames spores by nasal instillation 
in guinea pigs and rabbits were approximately 1 log greater 
than that for mice. Importantly, the LD50  of  B. anthracis 
Ames spores by aerosolization to Dutch-belted rabbits was 
determined earlier to be 1 x 10
5 cfu, which was the same as 
the nasal instillation dose [4, 56]. 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Survival of Dutch-belted rabbits treated with 14.3 mg/kg/day of levofloxacin beginning at various times after challenge with 100 
LD50 B. anthracis Ames spores by nasal instillation. Levofloxacin was given for 13 days following the challenge of each group. Groups that 
initiated treatment at 24 and 48 h, were significant beginning at day 3, however, the 48 h group was only significant until day 7, while the 24 
h group was significant through the end of the study. All other groups were not significant. Significance from the control was determined by 
the Fisher Exact Test (p<0.05). Protection Against Anthrax, Plague, and Tularemia  The Open Microbiology Journal, 2010, Volume 4    41 
  It was interesting to note in the mouse models that the 
ED50 for levofloxacin against B. anthracis was approxi-
mately 40-fold higher than the ED50 for Y. pestis (ED50=0.7). 
Similar results were observed with levofloxacin against B. 
anthracis and F. tularensis in BALB/c mice (ED50=0.1). We 
suspect that the basis for these observed differences in ED50s 
is multifactorial and could be related to the number of bacte-
ria constituting the challenge dose (5 LD50), rather than to 
the potency of levofloxacin against Gram-negative versus 
Gram-positive bacteria. Alternatively, the resistance of 
spores to antibiotics and chemicals and/or the presence of 
capsule around B. anthracis vegetative cells could have   
affected the antibiotic dose or exposure needed to reduce the 
bacterial load. In fact, the MICs with levofloxacin and cipro-
floxacin for B. anthracis Ames and Y. pestis CO92 were 
each determined to be 0.03 μg/ml, while for F. tularensis it 
was 0.03 μg/ml with levofloxacin and 0.01 μg/ml with cipro-
floxacin. In addition, a recent study examining the spore 
subpopulations suggested suppression of resistance required 
greater drug exposure with more frequent antibiotic dosing 
[57]. 
  It is also plausible that, differences between the three 
organisms with respect to ED50/ED100 doses of the two   
quinolones may be illustrating variations in the immune   
response related to the various virulence factors and the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). A. Survival of Swiss-Webster mice treated with various doses of levofloxacin for six days starting 24 h after challenge with 5 LD50 
of Y. pestis C092 cells by nasal instillation. The horizontal bar indicates the period of levofloxacin treatment. Complete protection against 
primary challenge was achieved by a dose of 5 mg/kg/day levofloxacin. Significance for all groups began at day 3, and while the two lowest 
doses were only significant for this time point, all other groups were significant until day 32. Significance from the control was determined 
by the Fisher Exact Test (p<0.05). B. Survival of Swiss-Webster mice challenged with Y. pestis C092 followed treatment with 5 or 10 
mg/kg/day of Levofloxacin at various times post challenge. Animals were dosed for 6 days, once initiated, and survival was compared to the 
control group (no levofloxacin). Significance (p<0.05) for all treatment groups from the control group began at day 3. Both doses of 
levofloxacin at 24 and 36 h postchallenge were significantly different (p<0.05) from the control group until the end of the study, but at 48 h 
both 5 and 10mg/kg groups were not significantly different from the control group (p>0.05). 42    The Open Microbiology Journal, 2010, Volume 4  Peterson et al. 
known immunomodulatory properties of ciprofloxacin and 
levofloxacin [42]. For example, the down-regulation of LPS-
mediated proinflammatory cytokine production associated 
with fluoroquinolone administration may, in part, explain 
why lower effective doses are needed for infection with en-
dotoxin-producing F. tularensis and Y. pestis, as compared 
to infection with B. anthracis. Clearly, further study of the 
indirect effect of fluoroquinolones on the immune response 
following infection with these pathogens is needed to ad-
dress this speculation.  
  Our results illustrated that levofloxacin is an effective 
antibiotic in protecting experimental animals against all three 
bacterial infections; however, the fluoroquinolones appeared 
more potent in their in vivo bactericidal effect against   
pneumonic plague and tularemia, than against inhalation 
anthrax.  
  The serum concentrations and pharmacokinetic parame-
ters of ciprofloxacin and levofloxacin were nearly identical 
in the guinea pig and rabbit models despite the slightly 
higher ED100 dosage of ciprofloxacin required to obtain the 
same effectiveness in the survival studies. Therefore, with 
respect to these two models, there appears to be concordance 
between ED50/ED100 doses, fluoroquinolone concentrations 
and a desirable therapeutic effect. In addition, the serum 
concentrations and the derived kinetic parameters are consis-
tent with the published literature [40, 47, 58, 59]. The noted 
limitation of these concentration data is the fact they were 
obtained in uninfected animals and involved single-dose 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). A. Survival of BALB/c mice challenged with 3 LD50 F. tularensis SCHU S4 by nasal instillation followed by treatment with various 
doses of levofloxacin. The horizontal bar indicates the period of treatment (13 days). Significance from the control was determined by the 
Fisher Exact Test (p<0.05), and all of the groups of mice except for the 0.1 mg/kg/day dose of levofloxacin were significant. B. Survival of 
BALB/c mice challenged with F. tularensis SCHU S4 followed by treatment with 40 mg/kg/day starting at various times post challenge. The 
period of treatment was 13 days. Significance from the control was determined by the Fisher Exact Test (p<0.05) and all of the groups of 
mice, except for the one to which antibiotic treatment, was administered 120 h postinfection, were significant. Protection Against Anthrax, Plague, and Tularemia  The Open Microbiology Journal, 2010, Volume 4    43 
administration. The approximate Cmax/MIC ratios for cipro-
floxacin and levofloxacin in guinea pigs and rabbits were 70 
and 40-80, respectively. The corresponding AUC/MIC ratios 
were approximately 150-175 and 160-200. These values are 
well above the Cmax/MIC ratio of 19.6-33.8 (rhesus mon-
keys) and AUC/MIC ratio of 15.8-30 (murine) that have 
been associated with bacterial eradication and clinical out-
comes reported from recent pharmacodynamic experiments 
specifically involving infection with B. anthracis [23, 37, 
40-41]. Deziel et al. [37] reported AUC/MIC ratios of ap-
proximately 200-300 were needed for effective therapy; 
however, outcome was highly dependent on the animal 
model used and frequency of dose administration. Finally, 
the Cmax/MIC and AUC/MIC ratios determined from data in 
the present study may have been even higher in infected 
animals with diminished hepatic and renal elimination   
receiving multiple-dose administration [58].  
  The extremely high 90 mg/kg dose of both ciprofloxacin 
and levofloxacin required for 100% efficacy against B. an-
thracis in mice resulted in roughly dose-dependent increases 
in Cmax and AUC parameters. These values correspond to 
Cmax/MIC and AUC/MIC ratios of 800 to nearly 1900. 
Therefore, the observed differences between animal species 
with regard to B. anthracis infection are not readily ex-
plained on the basis of achievable serum concentrations rela-
tive to the MIC; however, it has been suggested that other 
pharmacodynamic parameters such as time above the MIC 
(T>MIC) may be an important determinant of outcome for 
the metabolically inactive spore population that may germi-
nate at antibiotic concentrations at or below the MIC [37, 40, 
57]. In addition, this disparity among models may be related 
to species-specific immune response interactions to the viru-
lence factors associated with B. anthracis.  
 Regardless,  the  ED100 for ciprofloxacin in rabbits given 
by the i.m. route was 10 mg/kg/day for anthrax. In human 
adults, the recommended dose for ciprofloxacin for   
inhalational anthrax by the oral route is 400-500 mg   
(5.7-7.1 mg/kg for an average 70 kg body weight) every 12 h 
for 60 days. For the highest oral dose, the equivalent in-
jectable (i.v.) dose of ciprofloxacin is 400 mg every 12 h 
Table 2.  Summary of Pharmacokinetic Data in Three Animal Species Dosed with Ciprofloxacin or Levofloxacin 
Regimen (Drug-mg/kg-Route)  Cmax (g/ml)  Tmax (h)  AUC0-6h (g·h/ml)  AUC0-h (g·h/ml)  T (h)  TBC (ml/min) 
Swiss-Webster Mice 
Cip-90-ip  25.5 ± 4.5@  0.25  56.5  62.1  1.8  0.80 
Lev-5-ip  13.4 ± 6.3  0.25  14.6  16.7  2.1  0.17 
Lev-90-ip  45.2 ± 10.3#@  0.25  36.2  37.4  1.7  1.33 
Hartley Guinea Pigs 
Cip-15-sc  2.2 ± 1.0  1.0 (0.25-1.5)  5.0 ± 0.6  5.5 ± 0.7  1.4 ± 0.2  18.0 ± 2.4 
Lev-8.5-sc  2.7 ± 2.1  1.0 (0.25-1.5)  3.8 ± 0.9  6.6 ± 3.3  1.7 ± 0.6  10.5 ± 4.2 
Dutch-Belted Rabbits 
Cip-10-im  2.3 ± 1.5  0.63 (0.25-2)  3.2 ± 0.5  5.3 ± 1.9  1.5 ± 0.7  32.9 ± 11.7 
Lev-7.1-im  1.2 ± 0.2  1.25 (1-1.5)  3.3 ± 0.5  5.1 ± 1.7  2.8 ± 1.2*  31.3 ± 10.1 
Data given as mean ± S.D except Tmax given as median (range); *P=0.009, Lev-7.1 vs Cip-10; #P=0.013, Lev-90 vs Cip-90;@P=<0.001, Cip-90 and Lev-90 vs Lev-5. 
Note: composite nature of most PK parameters in mice prevents statistical analysis. 
AUC = Area Under Curve (Total drug exposure over time course). 
TBC = Total Body Clearance. 
 
Table 3.  Summary of In Vivo ED50 and ED100 Values During Treatment with Fluoroquinolones Against B. anthracis, Y. pestis, and 
F. tularensis Following Challenge by Nasal Instillation 
ED50 (mg/kg/day) / ED100 (mg/kg/day) 
Animal  Antibiotic  B. anthracis Ames Spores  Y. pestis CO92 Cells  F. tularensis SCHU S4 Cells 
Ciprofloxacin 70/90  N.D.  N.D. 
Swiss-Webster Mice 
Levofloxacin 28/90  0.7/5.0  0.1/5.0 
Ciprofloxacin 8.8/15  N.D.  N.D. 
Hartley Guinea Pig 
Levofloxacin 5.0/17  N.D.  N.D. 
Ciprofloxacin 7.5/10  N.D.  N.D. 
Dutch-belted Rabbit 
Levofloxacin 4.0/7.0  N.D.  N.D. 44    The Open Microbiology Journal, 2010, Volume 4  Peterson et al. 
(http://www.globalrph.com/ciprofloxacin_dilution.htm.). 
Likewise, the recommended levofloxacin dose for adult   
human use is 500 mg/day (7.1 mg/kg/day), and the ED100 in 
rabbits for levofloxacin is 7 mg/kg/day. These ED100 doses 
of ciprofloxacin and levofloxacin in rabbits seem compara-
ble to human doses; however, these data should be inter-
preted very cautiously as several body physiological func-
tions play key roles in determining antibiotic concentrations 
effective in a patient.  
  In mouse and guinea pig models, it was clear that short-
term therapy with either ciprofloxacin or levofloxacin was 
not capable of providing long term protection against B. an-
thracis, since cessation of antibiotic treatment resulted in 
deaths of the animals. The basis for this observation pre-
sumably is due to the inability of the antibiotic to kill all the 
spores. However, long-term protection from antibiotics in 
rabbits appeared superior. Whether this could be related to 
differences in spore germination in rodents versus rabbits is 
not known. Asynchronous or delayed germination is be-
lieved to be an important problem in patients that has caused 
physicians to prescribe long-term courses of antibiotic treat-
ment (e.g., 60 days or longer). This medical strategy was 
based upon the report that the majority of nonhuman pri-
mates, challenged with aerosols of B. anthracis spores, were 
protected against anthrax infection when treated for 60 days; 
however, superior protection was conferred by administering 
a combination of ciprofloxacin and vaccination with protec-
tive antigen (PA) [60]. It is also possible that the fluoroqui-
nolones exert differential immunomodulatory effects on the 
innate immune responses of rodents versus rabbits. Indeed 
our own studies have also indicated a synergistic protective 
effect in mice and guinea pigs against anthrax when cipro-
floxacin was combined with monoclonal antibodies against 
protective antigen (PA) of B. anthracis [4].  
  Despite the effectiveness of the fluoroquinolones in treat-
ing inhalation anthrax, as demonstrated in these animal mod-
els, resistance to fluoroquinolones is emerging among other 
bacteria that cause clinical infections [61-63]. It is also im-
portant to consider the possibility of bacteria acquiring resis-
tance to a particular antibiotic during treatment. Further, 
physicians must have other effective antibiotics to prescribe 
in the event of a bioterrorism attack involving a B. anthracis 
strain or other bacterial threat agents carrying multiple anti-
biotic resistance factors. This scenario is of particular con-
cern because additional time is required to ascertain the anti-
biotic susceptibility profile of the bacteria, and the models 
indicate that prompt initiation of appropriate antibiotic ther-
apy postexposure is essential to prevent a lethal infection 
with any of these select agents. 
  Treatment with levofloxacin, is also very effective 
against plague and tularemia and a 6-13 day treatment 24 h 
post infection resulted in 100% protection. Therefore, 
levofloxacin could be a drug of choice for all of the three 
category A select bacterial agents. Recently, antibiotic-
resistant strains of Y. pestis emerged that were isolated from 
human cases of bubonic plague in Madagascar [64, 65]. 
These plague isolates with natural resistance to antibiotics 
contained transmissible plasmids; in one case, the plasmid 
possessed multi-drug resistant determinants for chloram-
phenicol acetyltransferase, streptomycin-modifying enzyme 
and TEM-1 beta-lactamase; and in the other case, the plas-
mid encoded high-level resistance to streptomycin. The 
bioweapon programs of the Former Soviet Union engineered 
drug-resistant variants of highly pathogenic B. anthracis 
strains specific for at least 10 different antibiotics (including 
the fluoroquinolones) [66]. Similarly, spontaneous-resistant 
mutants of B. anthracis Sterne have been isolated that were 
resistant to 18 different antibiotics [67]. The same could be 
true for Y. pestis and F. tularensis. Therefore, studies should 
continue to develop new therapeutics and antibiotics against 
these deadly pathogens, as currently there are no vaccines for 
plague and tularemia. Further, although Biothrax vaccine 
(Emergent Biosolutions, Gaithersburg, MD) is available for 
anthrax, it provides short-term protection and requires multi-
ple injections.  
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